Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zelnorm returns

Executive Summary

Novartis drug will be available under a treatment investigational new drug protocol to treat irritable bowel syndrome with constipation and chronic idiopathic constipation in women under 55, FDA announces July 27. Marketing of tegaserod maleate was suspended in March after a pooled data analysis of 29 clinical trials revealed a higher chance of heart attack, stroke and worsening heart chest pain in patients treated with Zelnorm compared to those on placebo (1"The Pink Sheet" April 2, 2007, p. 3)...
Advertisement

Related Content

Door Open For Zelnorm Return Despite Marketing “Suspension,” Novartis Says
Door Open For Zelnorm Return Despite Marketing “Suspension,” Novartis Says
Advertisement
UsernamePublicRestriction

Register

PS048634

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel